Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes

被引：102

作者：

Storgaard, Heidi ^{[1
]}

Cold, Frederik ^{[1
]}

Gluud, Lise L. ^{[2
,3
]}

Vilsboll, Tina ^{[1
,3
]}

Knop, Filip K. ^{[1
,3
,4
]}

机构：

[1] Univ Copenhagen, Gentofte Hosp, Ctr Diabet Res, Hellerup, Denmark

[2] Univ Copenhagen, Hvidovre Hosp, Gastrounit, Hvidovre, Denmark

[3] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark

[4] Univ Copenhagen, Fac Hlth & Med Sci, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark

来源：

DIABETES OBESITY & METABOLISM | 2017年 / 19卷 / 06期

关键词：

antidiabetic drug; GLP-1; analogue; incretin therapy; liraglutide; meta-analysis; type; 2; diabetes; INCRETIN-BASED THERAPIES; METAANALYSIS; LIRAGLUTIDE; ASSOCIATION; SAFETY; DRUGS;

D O I：

10.1111/dom.12885

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Glucagon-like peptide-1 receptor agonist (GLP-1RAs) labels warn about acute pancreatitis (AP) and impose upon doctors the obligation to inform patients about symptoms of AP. Here we systematically reviewed the risk of AP in randomized placebo-controlled trials (RCTs) investigating the effect of GLP-1RAs in type 2 diabetes. We performed a systematic review with meta-analysis of long-term (minimum 24 months), placebo-controlled GLP-1RA RCTs in which AP was a predefined adverse event and adjudicated by blinded and independent adjudicating committees. Three high-quality RCTs included a total of 9347 GLP-1RA-treated and 9353 placebotreated patients with type 2 diabetes. Compared to placebo, treatment with GLP1-RA was not associated with increased risk of AP (Peto odds ratio 0.745 [95% CI, 0.47-1.17]). Trial Sequential Analysis suggested that additional evidence is needed. In conclusion, this review found no evidence that treatment with GLP-1RA increases the risk of AP in patients with type 2 diabetes.

引用

收藏

页码：906 / 908

页数：3

相关论文

共 14 条

[1] Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta-analysis of randomized controlled cardiovascular outcome trials [J].

Abbas, A. S. ;

Dehbi, H. -M. ;

Ray, K. K. .

DIABETES OBESITY & METABOLISM, 2016, 18 (03) :295-299

[2] Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis [J].

Azoulay, Laurent ;

Filion, Kristian B. ;

Platt, Robert W. ;

Dahl, Matthew ;

Dormuth, Colin R. ;

Clemens, Kristin K. ;

Durand, Madeleine ;

Hu, Nianping ;

Juurlink, David N. ;

Paterson, J. Michael ;

Targownik, Laura E. ;

Turin, Tanvir C. ;

Ernst, Pierre .

JAMA INTERNAL MEDICINE, 2016, 176 (10) :1464-1473

[3]

Center for Drug Evaluation and Research, 2008, FDA DRUG SAF NEWSL P, V1

[4] Pancreatic Safety of Incretin-Based Drugs - FDA and EMA Assessment [J].

Egan, Amy G. ;

Blind, Eberhard ;

Dunder, Kristina ;

de Graeff, Pieter A. ;

Hummer, B. Timothy ;

Bourcier, Todd ;

Rosebraugh, Curtis .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (09) :794-797

[5] Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1-Based Therapies [J].

Elashoff, Michael ;

Matveyenko, Aleksey V. ;

Gier, Belinda ;

Elashoff, Robert ;

Butler, Peter C. .

GASTROENTEROLOGY, 2011, 141 (01) :150-156

[6] Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies [J].

Giorda, Carlo B. ;

Sacerdote, Carlotta ;

Nada, Elisa ;

Marafetti, Lisa ;

Baldi, Ileana ;

Gnavi, Roberto .

ENDOCRINE, 2015, 48 (02) :461-471

[7] Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies [J].

Li, Ling ;

Shen, Jiantong ;

Bala, Malgorzata M. ;

Busse, Jason W. ;

Ebrahim, Shanil ;

Vandvik, Per Olav ;

Rios, Lorena P. ;

Malaga, German ;

Wong, Evelyn ;

Sohani, Zahra ;

Guyatt, Gordon H. ;

Sun, Xin .

BMJ-BRITISH MEDICAL JOURNAL, 2014, 348

[8] Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes [J].

Marso, Steven P. ;

Daniels, Gilbert H. ;

Brown-Frandsen, Kirstine ;

Kristensen, Peter ;

Mann, Johannes F. E. ;

Nauck, Michael A. ;

Nissen, Steven E. ;

Pocock, Stuart ;

Poulter, Neil R. ;

Ravn, Lasse S. ;

Steinberg, William M. ;

Stockner, Mette ;

Zinman, Bernard ;

Bergenstal, Richard M. ;

Buse, John B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (04) :311-322

[9] Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome [J].

Pfeffer, Marc A. ;

Claggett, Brian ;

Diaz, Rafael ;

Dickstein, Kenneth ;

Gerstein, Hertzel C. ;

Kober, Lars V. ;

Lawson, Francesca C. ;

Ping, Lin ;

Wei, Xiaodan ;

Lewis, Eldrin F. ;

Maggioni, Aldo P. ;

McMurray, John J. V. ;

Probstfield, Jeffrey L. ;

Riddle, Matthew C. ;

Solomon, Scott D. ;

Tardif, Jean-Claude .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (23) :2247-2257

[10] Glucagonlike Peptide 1-Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus A Population-Based Matched Case-Control Study [J].

Singh, Sonal ;

Chang, Hsien-Yen ;

Richards, Thomas M. ;

Weiner, Jonathan P. ;

Clark, Jeanne M. ;

Segal, Jodi B. .

JAMA INTERNAL MEDICINE, 2013, 173 (07) :534-539